An artificial-intelligence approach created at Carolina could help bring new drugs to patients quicker.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
The system is called Reinforcement Learning for Structural Evolution, known as ReLeaSE, and is an algorithm and computer program that comprises two neural networks which can be thought of as a teacher and a student. The teacher knows the syntax and linguistic rules behind the vocabulary of chemical structures for about 1.7 million known biologically active molecules. By working with the teacher, the student learns over time and becomes better at proposing molecules that are likely to be useful as new medicines.
Alexander Tropsha, Olexandr Isayev and Mariya Popova, all of the UNC Eshelman School of Pharmacy, are the creators of ReLeaSE. The University has applied for a patent for the technology, and the team published a proof-of-concept study in the journal Science Advances last week.
“If we compare this process to learning a language, then after the student learns the molecular alphabet and the rules of the language, they can create new ‘words,’ or molecules,” said Tropsha. “If the new molecule is realistic and has the desired effect, the teacher approves. If not, the teacher disapproves, forcing the student to avoid bad molecules and create good ones.”
ReLeaSE is a powerful innovation to virtual screening, the computational method widely used by the pharmaceutical industry to identify viable drug candidates. Virtual screening allows scientists to evaluate existing large chemical libraries, but the method only works for known chemicals. ReLeASE has the unique ability to create and evaluate new molecules.
“A scientist using virtual screening is like a customer ordering in a restaurant. What can be ordered is usually limited by the menu,” said Isayev. “We want to give scientists a grocery store and a personal chef who can create any dish they want.”
The team has used ReLeaSE to generate molecules with properties that they specified, such as desired bioactivity and safety profiles.The team used the ReLeaSE method to design molecules with customized physical properties, such as melting point and solubility in water, and to design new compounds with inhibitory activity against an enzyme that is associated with leukemia.
“The ability of the algorithm to design new, and therefore immediately patentable, chemical entities with specific biological activities and optimal safety profiles should be highly attractive to an industry that is constantly searching for new approaches to shorten the time it takes to bring a new drug candidate to clinical trials,” said Tropsha.
The Latest on: Drug design
via Google News
The Latest on: Drug design
- Azide-linkers for Drug Designon October 10, 2019 at 9:13 am
“Click chemistry” continues to gain popularity and is used in a variety of research fields with significant contributions to the fields of bioconjugation and drug discovery. Advantages: Wide in scope.
- Catalent to Discuss How Drug Design Influences Patient Outcomes at PODDon October 2, 2019 at 5:42 pm
On Tuesday, Oct. 8 at 1:20 p.m., Cornell Stamoran, Ph.D., Founder and Co-Chair of the Catalent Applied Drug Delivery Institute, will moderate the "Smart Drug Design and Development – from Candidate to ...
- Topic: drug designon September 30, 2019 at 5:00 pm
The number of pediatric drug approvals has increased 5 fold over the last 20 years, rising from 10-20 approvals per year to 50-60 annually today. Increased awareness around pediatric medicine and FDA ...
- Bayer using AI to improve disease diagnosis, drug designon September 29, 2019 at 7:44 am
Bayer's AI project head discusses work using artificial intelligence to patient data to speed disease diagnosis, recommend the best treatment and improve drug design and testing. Written by By LINDA A ...
- Bayer using AI to improve disease diagnosis, drug designon September 29, 2019 at 7:01 am
Q: How are you using AI to improve design and patient testing of experimental drugs? A: When developing a new drug, we can model how it will behave in a cell in combination with other drugs the ...
- The Master Key To Drug Design: Multi-Target Drugson September 16, 2019 at 7:00 am
According to a 2018 Deloitte report, returns on research and development for the top 12 pharma companies have declined to 1.9% from 10.1% in 2010, the cost to bring a drug to market has increased and ...
via Bing News